Rethinking Kidney Cancer Surgery: Is Less Really More?
"A critical look at when removing lymph nodes during kidney cancer surgery is beneficial, and when it might be doing more harm than good."
Cytoreductive nephrectomy (CN) is a complex surgical procedure performed under challenging circumstances. For years, it's been a standard approach, particularly in the immunotherapy era, based on the idea that removing as much of the cancer as possible improves survival. However, recent prospective studies are prompting experts to reconsider the extent of surgery needed, specifically whether routine lymph node removal (lymphadenectomy or LND) is always necessary during CN.
In a recent study published in the CUAJ, Patel and colleagues delved into this issue using data from the Surveillance, Epidemiology, and End Results (SEER) registry. Their findings challenge the conventional approach, suggesting that LND may not provide a therapeutic advantage in all cases. This has sparked a critical conversation within the medical community about tailoring surgical strategies to individual patient needs.
The study paints a detailed picture of metastatic kidney cancer treatment, considering the interplay between CN, LND, and patient outcomes. While survival rates for patients with newly diagnosed M1 (metastatic) disease remain less than a year on average, improvements have been observed over time. The association of CN with extended survival is noted, with consideration of potential selection biases in administrative data. What's particularly interesting is the suggestion that extensive node dissection doesn't necessarily improve survival, and in some cases, may even be linked to decreased overall and disease-specific survival.
Changing Surgical Patterns
A September 2025 study in the United States found that cytoreductive nephrectomy for metastatic kidney cancer has declined steadily over the past 15 years, particularly since newer cancer treatments became available. The same study reported that patients' likelihood of undergoing the surgery varies according to factors including patient characteristics. For localized and regional kidney cancer, the National Cancer Institute reports that complete nephrectomy has decreased since 2000 while partial nephrectomy has become more common.
A Selective Surgical Role
Cytoreductive nephrectomy removes a cancerous kidney, often before or alongside other treatments. Its role in metastatic renal cell carcinoma has been questioned since systemic targeted therapies became available, and retrospective observational studies have reported therapeutic benefit. However, the benefit remains unclear and depends on the patient's clinical condition and symptoms, while the procedure itself carries surgical risk.
Lymph Node Removal: When Does It Help?
The role of lymph node removal in kidney cancer surgery has been a topic of debate for years. The recent SEER registry study adds fuel to this discussion by suggesting that LND may not always be beneficial. This aligns with other studies that have questioned the value of routine LND during CN. One study by Trinh et al., also using SEER data, found that nodal disease worsened survival, with incremental declines observed with increased node burden.
- No Universal Benefit: Studies consistently show that routine lymph node dissection (LND) doesn't improve survival rates in all kidney cancer patients undergoing cytoreductive nephrectomy (CN).
- Potential Harm: In some cases, LND may be associated with decreased overall and disease-specific survival, suggesting it could be doing more harm than good.
- Node-Negative Patients: Clinically node-negative patients, in particular, don't seem to benefit from LND.
- Aggressive Disease: Patients with high-volume metastases or adverse prognostic factors are unlikely to benefit from LND, indicating that the procedure may not be effective in these advanced cases.
Reassessing Lymph Nodes and Surgery
The article "Rethinking lymph node metastasis and cytoreductive nephrectomy" was published on December 15, 2016. Its title identifies two connected questions in metastatic kidney cancer: how lymph node metastasis should be understood and how cytoreductive nephrectomy should be reconsidered. The source provides a focused review perspective rather than a newer publication date.
Tailoring the Surgical Approach: A Path Forward
So, what does this mean for surgeons treating patients with kidney cancer? It seems clear that a one-size-fits-all approach to lymph node removal is no longer appropriate. Clinically node-negative patients are unlikely to benefit from LND, and patients with high-volume metastases or numerous adverse prognostic factors may also be spared this procedure.
From Routine Surgery to Selection
Radical nephrectomy has traditionally been the standard treatment for nondisseminated kidney cancer, while the role of cytoreductive nephrectomy in metastatic disease has remained controversial. Earlier evidence evaluated arguments both for and against removing the primary kidney tumor in metastatic disease. More contemporary reviews state that systemic therapy is the priority for metastatic kidney cancer, while nephrectomy may still have a role for patients with limited metastases, favorable prognostic factors, or a favorable response after initial systemic therapy.
Limits of Real-World Evidence
A June 2026 PubMed report on cytoreductive nephrectomy in metastatic kidney cancer highlights important limitations in interpreting its findings. The analysis is retrospective and may be affected by selection bias. It also lacked granular information about systemic therapy, making it harder to separate the effects of surgery from differences in patients' medical treatment.
However, navigating the setting of small-volume, easily resectable node metastasis remains a challenge. While there is likely little harm from excising paracaval or para-aortic nodes in concert with the hilar dissection, the benefits are backed by intuition rather than data. On one side, leaving accessible disease behind feels unpalatable, and some with limited metastatic burden beyond the retroperitoneum may survive far beyond the median; it would seem unfair to leave cancer behind.
Ultimately, the decision to perform LND should be based on a careful assessment of the individual patient's risk factors, the extent of their disease, and the potential benefits and harms of the procedure. As research continues to evolve, robust prospective data to answer this question is unlikely forthcoming. Patients facing CN are in peril and we want to do something to help. Studies like this help to resolve where our efforts are best laid and when isn't actually more.